Resverlogix Publishes on Apabetalone's Potential for the Tre

Resverlogix Corp. today announced the publication of a peer-reviewed article, entitled Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human...

Related Keywords

Canada , United States , Toronto , Ontario , Canadian , Donald Mccaffrey , Ewelina Kulikowski , Alberta Newsfile Corp , Us Food Drug Administration , Resverlogix Corp , Twitter , Toronto Stock Exchange , Linkedin , Gene Expression , Primary Human , Highlights Include , Chief Scientific Officer , Breakthrough Therapy Designation , Drug Administration , Looking Statements , Annual Information Form , Markets ,